Philip Van Damme

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics

Steven Boeynaems, Elke Bogaert, Dénes Kovács et al. · Molecular Cell · 2017 · 532 citations · Full text

Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs

Jie Jiang, Qiang Zhu, Tania F. Gendron et al. · Neuron · 2016 · 530 citations · Full text

Natural Sciences, Als/ftd-linked Repeat Expansions, Molecular Biology +5

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model

Henk-Jan Westeneng, Thomas P. A. Debray, Anne E Visser et al. · The Lancet Neurology · 2018 · 492 citations · Full text

Prognostic Assessment, Neurodegenerative Diseases, Personalised Prediction Model +12

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

Constantin d’Ydewalle, Jyothsna Krishnan, Driss M Chiheb et al. · Nature Medicine · 2011 · 458 citations · Full text

Signal Transduction, Hdac6 Inhibitors, Signaling Pathway +11